A vaccine against S. pyogenes: Design and experimental immune response

Guilherme, Luiza; Postol, Edilberto; Barros, Samar Freschi; Higa, Fábio Takenori; Alencar, R.; Lastre, Miriam; Zayas, Caridad; Puschel, C; Silva, W. R.; Sá-Rocha, Luiz Carlos de; Sá-Rocha, Vanessa de Moura; Pérez, Oliver; Kalil, Jorge

doi:10.1016/j.ymeth.2009.03.024

Cited by 46 publications

(36 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Most of the available data are from high-income countries (84%), with limited data from low-income countries [25]. Minimal epitope J8/J14/p145 [33] Animal and natural infection studies Whole C-repeat conserved region [31,32] C-repeat epitope (StreptInCor vaccine) [47] C-repeat epitopes [48] Animal studies Carbohydrate GAS carbohydrate [49] Animal and natural infection studies…”

Section: Molecular Epidemiology Of Gas Infections and Implications Fomentioning

confidence: 99%

Group A streptococcal vaccines: Paving a path for accelerated development

Dale

Fischetti

Carapetis

et al. 2013

Vaccine

View full text Add to dashboard Cite

Section: Molecular Epidemiology Of Gas Infections and Implications Fomentioning

confidence: 99%

Group A streptococcal vaccines: Paving a path for accelerated development

Dale

Fischetti

Carapetis

et al. 2013

Vaccine

View full text Add to dashboard Cite

“…A third approach identified B-and T cell epitopes within the C-repeat region of the M5 protein leading to the construction of a 55-amino acid protein, designated StreptInCor (Guilherme et al 2006). Following subcutaneous immunization of BALB/c mice, StreptInCor co-administered with CFA/IFA was found to induce high titre serum IgG antibodies (Guilherme et al 2009). When StreptInCor was co-administered with the mucosal adjuvant, Adjuvant Finlay Cochleate 1, via the intranasal route, a mucosal IgA and systemic IgG response resulted (Guilherme et al 2009).…”

Section: Conserved C-repeat-based M Protein Vaccinesmentioning

confidence: 99%

“…Following subcutaneous immunization of BALB/c mice, StreptInCor co-administered with CFA/IFA was found to induce high titre serum IgG antibodies (Guilherme et al 2009). When StreptInCor was co-administered with the mucosal adjuvant, Adjuvant Finlay Cochleate 1, via the intranasal route, a mucosal IgA and systemic IgG response resulted (Guilherme et al 2009). A fourth approach utilized synthetic peptides based on minimal B-and T-cell epitopes.…”

Section: Conserved C-repeat-based M Protein Vaccinesmentioning

confidence: 99%

Group A Streptococcal Vaccine Candidates: Potential for the Development of a Human Vaccine

Henningham

Gillen

Walker

2012

Host-Pathogen Interactions in Streptococcal Diseases

View full text Add to dashboard Cite

Currently there is no commercial Group A Streptococcus (GAS; S. pyogenes) vaccine available. The development of safe GAS vaccines is challenging, researchers are confronted with obstacles such as the occurrence of many unique serotypes (there are greater than 150 M types), antigenic variation within the same serotype, large variations in the geographical distribution of serotypes, and the production of antibodies cross-reactive with human tissue which can lead to host auto-immune disease. Cell wall anchored, cell membrane associated, secreted and anchorless proteins have all been targeted as GAS vaccine candidates. As GAS is an exclusively human pathogen, the quest for an efficacious vaccine is further complicated by the lack of an animal model which mimics human disease and can be consistently and reproducibly colonized by multiple GAS strains.

show abstract

“…Many species of streptococci are members of the commensial microflora; they tend to colonize the upper respiratory tract and are highly virulent as they overcome the host defense system. Streptococcus pyogenes causes diseases such as severe invasive infections, the post-streptococcal sequelae of acute rheumatic fever and rheumatic heart disease, acute glomerulonephritis, and uncomplicated pharyngitis pyoderma, as well as cellulitis, bacteremia, necrotizing fasciitis, and toxic shock syndrome [6][7][8]. S. pyogenes is sensitive to the action of imidazole salts, and those compounds have been specifically analyzed to search for new and efficient drugs [9,10].…”

Section: Introductionmentioning

confidence: 99%

Prediction of antimicrobial activity of imidazole derivatives by artificial neural networks

et al. 2012

View full text Add to dashboard Cite

Abstract:The main goal of our study is the analysis of data obtained from molecular modeling for a series of imidazole derivatives that possess strong antifungal activity. The research was designed to use artificial neural network (ANN) analysis to determine quantitative relationships between the structural parameters and anti-Streptococcus pyogenes activity of a series of imidazole derivatives. ANN in association with quantitative structure-activity relationships (QSAR) represents a promising tool in the search for drug candidates among the practically unlimited number of possible derivatives. In this work, a series of 286 imidazole derivatives presented as cationic three-dimensional structures was used. The activity was expressed as a logarithm of the reciprocal of the minimal inhibitory concentrations, log 1/MIC. Multilayer perceptron ANN was used for predictions of antimicrobial potency of new imidazole derivatives on the basis of their structural descriptors. The obtained correlation coefficient equaled 0.9461 for the learning set, 0.9060 for the validation set and 0.8824 for the testing set of imidazole derivatives. Hence, satisfactory and practically useful predictions of antiStreptococcus pyogenes activity for a series of imidazole derivatives was obtained, supporting the future successful interpretation of QSAR analysis for those compounds.

show abstract

A vaccine against S. pyogenes: Design and experimental immune response

Cited by 46 publications

References 15 publications

Group A streptococcal vaccines: Paving a path for accelerated development

Group A streptococcal vaccines: Paving a path for accelerated development

Group A Streptococcal Vaccine Candidates: Potential for the Development of a Human Vaccine

Prediction of antimicrobial activity of imidazole derivatives by artificial neural networks

Contact Info

Product

Resources

About